Jaguar Health Announced Patent For Methods For Treating Congenital Diarrheal Disorders In Patients With An Inhibitor Of Chloride-Ion Transport Such As Crofelemer
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health has been granted a patent for methods to treat congenital diarrheal disorders (CDD) using crofelemer, an inhibitor of chloride-ion transport. The company is backing studies for crofelemer's use in rare diseases like microvillus inclusion disease and short bowel syndrome (SBS), with results anticipated in 2024.
January 04, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's new patent for crofelemer in treating CDDs could strengthen its market position in rare disease treatments, with potential revenue growth upon successful study results.
The issuance of a new patent typically provides a company with exclusive rights to market their product, which can lead to increased market share and revenue. As Jaguar Health is supporting studies for crofelemer in rare diseases, positive results in 2024 could further boost the drug's profile and sales potential. However, the impact is moderated by the fact that the study results are not immediate and the market for ultrarare CDDs is limited.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100